-
Lucidity in the Deeply Forgetful: A Scoping Review J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-03-05 John Paul Ross, Stephen G. Post, Laurel Scheinfeld
Abstract Background: Even in severe states of Alzheimer’s disease and related dementias (ADRD), accounts of an unexpected or paradoxical return of awareness and lucidity have been reported in some patients, documented formally, and studied. Objective: A scoping review was undertaken to survey the literature on the topic. Methods: Five databases were searched using pertinent search terms. Results were
-
The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer’s Disease: A Systematic Review and Meta-Analysis J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-03-05 Zhirui Li, Zixuan Fan, Qian Zhang
Background:Cerebrospinal fluid (CSF) or blood biomarkers like phosphorylated tau proteins (p-tau) are used to detect Alzheimer’s disease (AD) early. Increasing studies on cognitive function and blood or CSF p-tau levels are controversial. Objective:Our study examined the potential of p-tau as a biomarker of cognitive status in normal control (NC), mild cognitive impairment (MCI), and AD patients. Methods:We
-
Music Therapy as a Complementary Treatment in Patients with Dementia Associated to Alzheimer’s Disease: A Systematic Review J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-03-05 Eleonora Rossi, Francesco Marrosu, Luca Saba
Background:Alzheimer’s disease (AD) is a complex condition that affects various aspects of a patient’s life. Music therapy may be considered a beneficial supplementary tool to traditional therapies, that not fully address the range of AD manifestations. Objective:The purpose of this systematic review is to investigate whether music therapy can have a positive impact on AD patients and on which symptoms
-
Neurophysiological Alterations of the Visual Pathway in Posterior Cortical Atrophy: Systematic Review and a Case Series J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-03-05 Matteo Cotta Ramusino, Lucia Scanu, Linda Gritti, Camillo Imbimbo, Lisa Maria Farina, Giuseppe Cosentino, Giulia Perini, Alfredo Costa
Background:The clinical features of posterior cortical atrophy (PCA), a rare condition often caused by Alzheimer’s disease, have been recently defined, while little is known about its neurophysiological correlates. Objective:To describe neurophysiological alterations of the visual pathway as assessed using visual field test (VF), visual evoked potentials (VEP), and electroretinogram (ERG) in PCA patients
-
Obstructive Sleep Apnea and Alzheimer’s Disease Pathology: Is Sleep Architecture the Missing Key? J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-03-05 Joshua L. Gills, Omonigho M. Bubu
Impairments of the sleep architecture due to disrupted sleep in individuals with obstructive sleep apnea (OSA) may result in reduced slow wave sleep (SWS), intermittent hypoxemia, and excessive day time sleepiness— all factors that have been shown to impact Alzheimer’s disease (AD) risk. In this commentary, we comment on the work by Cavuoto and colleagues in which they examine the associations between
-
Neuropsychiatric and Cognitive Symptoms: Two Sides of the Same Coin? J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-03-05 Nikias Siafarikas
Neuropsychiatric symptoms (NPS) are increasingly being recognized as clinical markers for incipient dementia in Alzheimer’s disease (AD dementia). NPS may reinforce cognitive impairment or decline and vice versa. Although NPS are frequent already in mild cognitive impairment, their mechanisms are poorly understood. It is unclear if they share biological mechanisms with cognitive symptoms and how they
-
Machine Learning Predicts Conversion from Normal Aging to Mild Cognitive Impairment Using Medical History, APOE Genotype, and Neuropsychological Assessment J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-03-05 Divya Prabhakaran, Caroline Grant, Otto Pedraza, Richard Caselli, Arjun P. Athreya, Melanie Chandler
Background:Identifying individuals at risk for mild cognitive impairment (MCI) is of urgent clinical need. Objective:This study aimed to determine whether machine learning approaches could harness longitudinal neuropsychology measures, medical data, and APOE ɛ4 genotype to identify individuals at risk of MCI 1 to 2 years prior to diagnosis. Methods:Data from 676 individuals who participated in the
-
Inferring Alzheimer’s Disease Pathologic Traits from Clinical Measures in Living Adults J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-03-05 Jingjing Yang, Xizhu Liu, Shahram Oveisgharan, Andrea R. Zammit, Sukriti Nag, David A. Bennett, Aron S. Buchman
Background:Alzheimer’s disease neuropathologic changes (AD-NC) are important to identify people with high risk for AD dementia (ADD) and subtyping ADD. Objective:Develop imputation models based on clinical measures to infer AD-NC. Methods:We used penalized generalized linear regression to train imputation models for four AD-NC traits (amyloid-β, tangles, global AD pathology, and pathologic AD) in Rush
-
Adjunct Methods for Alzheimer’s Disease Detection: A Review of Auditory Evoked Potentials J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-02-13 Guoliang Wei, Xuelong Tian, Hong Yang, Yinpei Luo, Guisong Liu, Shuqing Sun, Xing Wang, Huizhong Wen
The auditory afferent pathway as a clinical marker of Alzheimer’s disease (AD) has sparked interest in investigating the relationship between age-related hearing loss (ARHL) and AD. Given the earlier onset of ARHL compared to cognitive impairment caused by AD, there is a growing emphasis on early diagnosis and intervention to postpone or prevent the progression from ARHL to AD. In this context, auditory
-
Interventions for Persons with Young-Onset Dementia and Their Families: A Scoping Review J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-02-13 Xiaoyan Cui, Junqiao Wang, Bei Wu, Qianhua Zhao, Xueting Tang, Jing Wang
Background: Dementia occurring before age 65 is known as young-onset dementia (YOD), with Alzheimer’s disease being the most common type. YOD poses unique challenges for persons and families, impacting their working-age years and family responsibilities. Person-centered interventions and services are essential to improve their quality of life and social engagement. Objective: This study aims to synthesize
-
Communication Regarding the Myocardial Ischemia/Reperfusion and Cognitive Impairment: A Narrative Literature Review J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-02-13 Haiqing Chang, Erya Chen, Tao Zhu, Jin Liu, Chan Chen
Abstract Coronary artery disease is a prevalent ischemic disease that results in insufficient blood supply to the heart muscle due to narrowing or occlusion of the coronary arteries. Various reperfusion strategies, including pharmacological thrombolysis and percutaneous coronary intervention, have been developed to enhance blood flow restoration. However, these interventions can lead to myocardial
-
High-Fat Diets in Animal Models of Alzheimer’s Disease: How Can Eating Too Much Fat Increase Alzheimer’s Disease Risk? J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Josue Valentin-Escalera, Manon Leclerc, Frédéric Calon
Abstract High dietary intake of saturated fatty acids is a suspected risk factor for neurodegenerative diseases, including Alzheimer’s disease (AD). To decipher the causal link behind these associations, high-fat diets (HFD) have been repeatedly investigated in animal models. Preclinical studies allow full control over dietary composition, avoiding ethical concerns in clinical trials. The goal of the
-
The Contributions of the Endolysosomal Compartment and Autophagy to APOE ɛ4 Allele-Mediated Increase in Alzheimer’s Disease Risk J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Ernest Amponsah Asiamah, Baofeng Feng, Ruiyun Guo, Xu Yaxing, Xiaofeng Du, Xin Liu, Jinyu Zhang, Huixian Cui, Jun Ma
Apolipoprotein E4 (APOE4), although yet-to-be fully understood, increases the risk and lowers the age of onset of Alzheimer’s disease (AD), which is the major cause of dementia among elderly individuals. The endosome-lysosome and autophagy pathways, which are necessary for homeostasis in both neurons and glia, are dysregulated even in early AD. Nonetheless, the contributory roles of these pathways
-
Single Cell Sequencing Technology and Its Application in Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Yuru Han, Congying Huang, Yuhui Pan, Xuefeng Gu
Alzheimer’s disease (AD) involves degeneration of cells in the brain. Due to insidious onset and slow progression, AD is often not diagnosed until it gets progressed to a more severe stage. The diagnosis and treatment of AD has been a challenge. In recent years, high-throughput sequencing technologies have exhibited advantages in exploring the pathogenesis of diseases. However, the types of cells of
-
O-GlcNAcylation and Its Roles in Neurodegenerative Diseases J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Pengyang Du, Xiaomin Zhang, Xia Lian, Christian Hölscher, Guofang Xue
As a non-classical post-translational modification, O-linked β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) is widely found in human organ systems, particularly in our brains, and is indispensable for healthy cell biology. With the increasing age of the global population, the incidence of neurodegenerative diseases is increasing, too. The common characteristic of these disorders is
-
The Catastrophe of Intracerebral Hemorrhage Drives the Capillary-Hemorrhage Dementias, Including Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Jonathan Stone, John Mitrofanis, Daniel M. Johnstone, Stephen R. Robinson
This review advances an understanding of several dementias, based on four premises. One is that capillary hemorrhage is prominent in the pathogenesis of the dementias considered (dementia pugilistica, chronic traumatic encephalopathy, traumatic brain damage, Alzheimer’s disease). The second premiseis that hemorrhage introduces four neurotoxic factors into brain tissue: hypoxia of the tissue that has
-
The Return of Biomarker Results in Research: Balancing Complexity, Precision, and Ethical Responsibility J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Julie M. Robillard, Mario Masellis, Susanna E. Martin, Ara S. Khachaturian, Roger A. Dixon
Abstract Recent research aimed at the discovery, integration, and communication of health outcome measures (or “biomarkers”) in Alzheimer’s disease has raised challenging questions related to whether, how and when results from these investigations should be disclosed to research participants. Reflecting the apparent heterogeneity of many neurodegenerative diseases, biomarker or other risk factor results
-
Misfolded α-Synuclein in Autosomal Dominant Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Laura Fort-Aznar, Laura Molina-Porcel, Oscar Ramos-Campoy, Diana Esteller, Laura Naranjo, Albert Lladó, Mircea Balasa, Raquel Ruiz-García, Anna Antonell, Raquel Sánchez-Valle
We analyzed Lewy body (LB) pathology in 18 autosomal dominant Alzheimer’s disease (ADAD) brains via immunohistochemistry. Real-time quaking induced conversion was used to detect misfolded α-synuclein (α-syn) in 18 living ADAD cerebrospinal fluid (CSF) samples. Concomitant LB pathology was present in 44% ADAD brains. Only 6% CSF samples were positive for misfolded α-syn. In an additional AD sample,
-
Rethinking Dementia Risk Prediction: A Critical Evaluation of a Multimodal Machine Learning Predictive Model J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Silvia Ottaviani, Fiammetta Monacelli
A recent study by Ding et al. explores the integration of artificial intelligence (AI) in predicting dementia risk over a 10-year period using a multimodal approach. While revealing the potential of machine learning models in identifying high-risk individuals through neuropsychological testing, MRIimaging, and clinical risk factors, the imperative of dynamic frailty assessment emerges for accurate
-
The Oxytocin Puzzle: Unlocking Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Maria Clara Selles, Mauricio Martins Oliveira
Alzheimer’s disease is a multi-factorial disease that disrupts many aspects of human behavior. In this comment, we highlight the work by Koulousakis et al. published in a recent issue of the Journal of Alzheimer’s Disease. In this study, the authors tested the therapeutic potential of the neuropeptide oxytocin in a pre-clinical model of Alzheimer’s disease and found positive behavioral outcomes on
-
Technology in Dementia Education: An Ethical Imperative in a Digitized World J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-30 Susanna E. Martin, Mallorie T. Tam, Julie M. Robillard
Abstract Technology can support the delivery of care and improve the lives of people living with dementia. However, despite a substantial body of evidence demonstrating the benefits and opportunities afforded by technology, gaps remain in how technology and technology ethics are addressed in dementia care education. Here we discuss disparities in current educational programming and highlight the ethical
-
Use of Complementary and Integrative Medicine for Alzheimer’s Disease and Cognitive Decline J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-16 Sarah A. Nguyen, Hanadi Ajam Oughli, Helen Lavretsky
Integrative medicine takes a holistic approach because it considers multiple aspects of the individual. This includes a person’s physical, emotional, interpersonal, behavioral, nutritional, environmental, and spiritual dimensions of wellbeing that contribute to the Whole Person Health. There is increasing interest and popularity of integrative approaches to treating cognitive decline and dementia because
-
Prevalence and Associations of Cognitive Impairment in Adult Patients with Moyamoya Disease: A Systematic Review and Meta-Analysis J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-16 Keith Z.X. Toh, Ming Yi Koh, Enver D.W. Loh, Ching-Hui Sia, Yaofeng Chong, Leonard L.L. Yeo, Vijay K. Sharma, Mervyn J.R. Lim, Benjamin Y.Q. Tan
Background:Cognitive impairment, and in the long term Alzheimer’s disease, vascular, or mixed dementia, are potential complications of moyamoya disease (MMD), of which the prevalence and associations are not well established. Objective:We performed a systematic review and meta-analysis to investigate the prevalence of cognitive impairment in adult patients with MMD as well as its clinical and demographic
-
The Carnitine Palmitoyl-Transferase 2 Cascade Hypothesis for Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-16 Hiskias G. Keizer, Ruud Brands, Ronald S. Oosting, Willem Seinen
Despite decades of intense research, the precise etiology of Alzheimer’s disease (AD) remains unclear. In this hypothesis, we present a new perspective on this matter by identifying carnitine palmitoyl transferase-2 (CPT2) as a central target in AD. CPT2 is an enzyme situated within the inner mitochondrial membrane, playing a crucial role in beta-oxidation of fatty acids. It exhibits high sensitivity
-
What Does ChatGPT Know About Dementia? A Comparative Analysis of Information Quality J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-16 Jill A. Dosso, Jaya N. Kailley, Julie M. Robillard
Abstract The quality of information about dementia retrieved using ChatGPT is unknown. Content was evaluated for length, readability, and quality using the QUEST, a validated tool, and compared against online material from three North American organizations. Both sources of information avoided conflicts of interest, supported the patient-physician relationship, and used a balanced tone. Official bodies
-
Odor Identification Across Time in Mutation Carriers and Non-Carriers in Autosomal-Dominant Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-16 Ove Almkvist, Maria Larsson, Caroline Graff
Abstract Background: Impaired odor identification is a characteristic of sporadic Alzheimer’sdisease(AD), but its presence in autosomal-dominantAD (adAD) remains uncertain. Objective: To investigate odor identification ability in mutation carriers (MC) and non-carriers (NC) of adAD in relation to years to estimated clinical onset clinical onset (YECO) of disease. Methods: Participants from six families
-
Effect of Vascular Risk Factors on Blood-Brain Barrier and Cerebrospinal Fluid Biomarkers Along the Alzheimer’s Disease Continuum: A Retrospective Observational Study J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-16 Francesco Ricci, Alessandro Martorana, Chiara G. Bonomi, Chiara Serafini, Nicola B. Mercuri, Giacomo Koch, Caterina Motta
Background: Blood-brain barrier (BBB) dysfunction could favor the pathogenesis and progression of Alzheimer’s disease (AD). Vascular risk factors (VRF) could worsen BBB integrity, thus promoting neurode generation. Objective: To investigate BBB permeability and its relation with VRF along the AD continuum (ADc). Cerebrospinal fluid (CSF) Amyloid (A) and p-tau (T) levels were used to stratify patients
-
Association Between Urinary Glyphosate Exposure and Cognitive Impairment in Older Adults from NHANES 2013-2014 J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-16 Jiawen Ren, Yongquan Yu, Yucheng Wang, Yu Dong, Xiaobing Shen
Background:Glyphosate is the most commonly used herbicide with potential neurotoxicity. However, limited epidemical evidence is found in the relationship between glyphosate and cognitive impairment, especially in the cognitive-disrupting sensitive elderly populations. Objective:This study aimed toexamine the association of urinary glyphosate exposure with cognitive impairment in the United State (US)
-
Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-16 Habbiburr Rehman, Ting Fang Alvin Ang, Qiushan Tao, Arielle Lauren Espenilla, Rhoda Au, Lindsay A. Farrer, Xiaoling Zhang, Wei Qiao Qiu
Background:Although cerebrospinal fluid (CSF) amyloid-β42 peptide (Aβ42) and phosphorylated tau (p-tau) and blood p-tau are valuable for differential diagnosis of Alzheimer’s disease (AD) from cognitively normal (CN) there is a lack of validated biomarkers for mild cognitive impairment (MCI). Objective:This study sought to determine how plasma and CSF protein markers compared in the characterization
-
Delirium Prevention in Early Rehabilitation During Acute Hospitalization and Implementation of Programs Specifically Tailored to Older Patients with Cognitive Impairment: A Scoping Review with Meta-Analysis J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Klaus Hauer, Ilona Dutzi, Christian Werner, Jürgen Bauer, Phoebe Ullrich
Background:No systematic review on delirium prevention within early, hospital-based rehabilitation on implementation of approaches specifically tailored for patients with cognitive impairment (PwCI), such as Alzheimer’s disease or vascular dementia, has been published despite the high relevance ofspecific medical care in this vulnerable population. Objective:To document design and effectiveness of
-
Sex and Sleep Disruption as Contributing Factors in Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Carrie E. Johnson, Marilyn J. Duncan, M. Paul Murphy
Alzheimer’s disease (AD) affects more women than men, with women throughout the menopausal transition potentially being the most under researched and at-risk group. Sleep disruptions, which are an established risk factor for AD, increase in prevalence with normal aging and are exacerbated in womenduring menopause. Sex differences showing more disrupted sleep patterns and increased AD pathology in women
-
Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Yunfeng Li, Xiongjin Chen, Mulan Zhou, Sifan Feng, Xiaoping Peng, Yan Wang
Alzheimer’s disease is a pervasive neurodegenerative disease that is estimated to represent approximately 70% of dementia cases worldwide, and the molecular complexity that has been highlighted remains poorly understood. The accumulation of extracellular amyloid-β (Aβ), intracellular neurofibrillary tangles formed by tau hyperphosphorylation, and neuroinflammation are the major pathological features
-
How Can We Use Mathematical Modeling of Amyloid-β in Alzheimer’s Disease Research and Clinical Practices? J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Chenyin Chu, Yi Ling Clare Low, Liwei Ma, Yihan Wang, Timothy Cox, Vincent Doré, Colin L. Masters, Benjamin Goudey, Liang Jin, Yijun Pan
The accumulation of amyloid-β (Aβ) plaques in the brain is considered a hallmark of Alzheimer’s disease (AD). Mathematical modeling, capable of predicting the motion and accumulation of Aβ, has obtained increasing interest as a potential alternative to aid the diagnosis of AD and predict disease prognosis. These mathematical models have provided insights into the pathogenesis and progression of AD
-
Investigating Sex Differences in Risk and Protective Factors in the Progression of Mild Cognitive Impairment to Dementia: A Systematic Review J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Jissa Martin, Natasha Reid, David D. Ward, Shannon King, Ruth E. Hubbard, Emily H. Gordon
Background:Developing effective strategies for reducing dementia risk requires a detailed understanding of the risk and protective factors associated with the progression of mild cognitive impairment (MCI) to dementia. Objective:We aimed to systematically review the evidence for sex differences inthese factors. Methods:Five online databases (PubMed/CINAHL/EMBASE/PsycINFO/Cochrane) were searched from
-
Sleep Biomarkers for Predicting Cognitive Decline and Alzheimer’s Disease: A Systematic Review of Longitudinal Studies J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Matteo Carpi, Mariana Fernandes, Nicola Biagio Mercuri, Claudio Liguori
Background: Sleep disturbances are considered a hallmark of dementia, and strong evidence supports the association between alterations in sleep parameters and cognitive decline in patients with mild cognitive impairment and Alzheimer’s disease (AD). Objective: This systematic review aims to summarize the existing evidence on the longitudinal association between sleep parameters and cognitive decline
-
A Meta-Analysis on Presynaptic Changes in Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Anne Anschuetz, Karima Schwab, Charles R. Harrington, Claude M. Wischik, Gernot Riedel
Abstract Background: A key aspect of synaptic dysfunction in Alzheimer’s disease (AD) is loss of synaptic proteins. Previous publications showed that the presynaptic machinery is more strongly affected than postsynaptic proteins. However, it has also been reported that presynaptic protein loss is highly variable and shows region- and protein-specificity. Objective: The objective of this meta-analysis
-
Patterns of Aging Changes in Bodyweight May Predict Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Svetlana Ukraintseva, Hongzhe Duan, Rachel Holmes, Olivia Bagley, Deqing Wu, Arseniy Yashkin, Alexander Kulminski, Igor Akushevich, Heather Whitson, Eric Stallard, Anatoliy Yashin, Konstantin Arbeev
Abstract Relationships between patterns of aging-changes in bodyweight and AD are not fully understood. We compared mean age-trajectories of weight between those who did and did not develop late-onset-AD, and evaluated impact of age at maximum weight (AgeMax), and slope of decline in weight, on AD risk. Women with late-onset-AD had lower weight three or more decades before AD onset, and ∼10 years younger
-
Herpes Simplex Virus 1 Infection Does Not Increase Amyloid-β Pathology in APP/PS1 Mice J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2024-01-02 Lina Lapeyre, Jocelyne Piret, Chantal Rhéaume, Vincent Pons, Olus Uyar, Paul Préfontaine, Serge Rivest, Guy Boivin
Using APP/PS1 mice that overproduce amyloid-β (Aβ) peptides, we investigated whether intranasal infection with a neurovirulent clinical strain of herpes simplex virus 1 (HSV-1) before Aβ deposition could accelerate or increase Alzheimer’s disease-like pathology. After HSV-1 infection, APP/PS1 micepresented a similar disease as wild type animals based on body weight changes, clinical symptoms, and survival
-
Neuropsychological Assessment of Older Adults in Nepal for Population-Based Dementia Ascertainment: Needs, Challenges, and Opportunities J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Emily M. Briceño, Usha Dhakal, Uttam Sharma, Nabin Adhikari, Meeta S. Pradhan, Lochana Shrestha, Pankaj Jalan, Janak Rai, Kenneth M. Langa, Jinkook Lee, Dirgha Ghimire, Carlos F. Mendes de Leon
The population of Nepal is rapidly aging, as in other low and middle-income countries, and the number of individuals living with Alzheimer’s Disease and related dementias (ADRD) is expected to increase. However, information about the neuropsychological assessment of ADRD in Nepal is lacking. We first aimed to examine the needs, challenges, and opportunities associated with the neuropsychological assessment
-
Diet’s Role in Modifying Risk of Alzheimer’s Disease: History and Present Understanding J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 William B. Grant, Steven M. Blake
Abstract Diet is an important nonpharmacological risk-modifying factor for Alzheimer’s disease (AD). The approaches used here to assess diet’s role in the risk of AD include multi-country ecological studies, prospective and cross-sectional observational studies, and laboratory studies. Ecological studies have identified fat, meat, and obesity from high-energy diets as important risk factors for AD
-
NLRP3 Inflammasome: An Emerging Therapeutic Target for Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Shuqi Tao, Wenyuan Fan, Jinmeng Liu, Tong Wang, Haoning Zheng, Gaoxiu Qi, Yanchun Chen, Haoyun Zhang, Zhangyu Guo, Fenghua Zhou
Alzheimer’s disease (AD) is currently the most prevalent neurological disease, and no effective and practical treatments and therapies exist. The nucleotide-binding oligomerization domain-, leucine-rich repeat-, and pyrin domain- containing receptor 3 (NLRP3) inflammasome is vital in the human innate immune response. However, when the NLRP3 inflammasome is overactivated by persistent stimulation, several
-
Multifactorial Causation of Alzheimer’s Disease Due to COVID-19 J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Paloma Monllor, Pratyush Kumar, Mari-Ángeles Lloret, Artemis Ftara, Jose-Luis Leon, Begoña Lopez, Ana Cervera-Ferri, Ana Lloret
There are several implications of the surge in the incidence of pandemics and epidemics in the last decades. COVID-19 being the most remarkable one, showed the vulnerability of patients with neurodegenerative diseases like Alzheimer’s disease (AD). This review studies the pathological interlinks and triggering factors between the two illnesses and proposes a multifactorial pathway of AD causation due
-
Systems Medicine as a Strategy to Deal with Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Xiao Xue Zeng, Jie Bangzhe Zeng
The traits of Alzheimer’s disease (AD) include amyloid plaques made of Aβ1-40 and Aβ1-42, and neurofibrillary tangles by the hyperphosphorylation of tau protein. AD is a complex disorder that is heterogenous in genetical, neuropathological, and clinical contexts. Current available therapeutics areunable to cure AD. Systems medicine is a strategy by viewing the body as a whole system, taking into account
-
Physical Performance and Amyloid-β in Humans: A Systematic Review and Meta-Analysis of Observational Studies J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Patricio Solis-Urra, María Rodriguez-Ayllon, Miriam Álvarez-Ortega, Cristina Molina-Hidalgo, Pablo Molina-Garcia, Cristina Arroyo-Ávila, Antonio García-Hermoso, Audrey M. Collins, Shivangi Jain, Juan Domingo Gispert, Teresa Liu-Ambrose, Francisco B. Ortega, Kirk I. Erickson, Irene Esteban-Cornejo
Background:Accumulation of amyloid-β (Aβ) plaques is one of the main features of Alzheimer’s disease (AD). Physical performance has been related to dementia risk and Aβ, and it has been hypothesized as one of the mechanisms leading to greater accumulation of Aβ. Yet, no evidence synthesis has beenperformed in humans. Objective:To investigate the association of physical performance with Aβ in humans
-
Paving the Way for Alzheimer’s Disease Prevention: A Systematic Review of Global Open-Access Neuroimaging Datasets in Healthy Individuals J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Maria Ly, Gary Z. Yu, Won Jong Chwa, Cyrus A. Raji
Background:Given the advent of large-scale neuroimaging data-driven endeavors for Alzheimer’s disease, there is a burgeoning need for well-characterized neuroimaging databases of healthy individuals. With the rise of initiatives around the globe for the rapid and unrestricted sharing of data resources, there is now an abundance of open-source neuroimaging datasets available to the research community
-
Bilingual Primary Progressive Aphasia: A Scoping Review of Assessment and Treatment Practices J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Stephanie M. Grasso, Camille A. Wagner Rodríguez, Núria Montagut Colomer, Sonia-Karin Marqués Kiderle, Raquel Sánchez-Valle, Miguel Ángel Santos Santos
Background:Primary progressive aphasia (PPA) is a neurodegenerative syndrome characterized by speech and/or language impairment with relatively spared cognition. Research investigating behavioral speech-language intervention and methods for cognitive-linguistic assessment in PPA has predominantly centered around monolingual speakers. This gap hinders the widespread adoption of evidence-based approaches
-
Association Between Olfactory Dysfunction and Cognitive Impairment in Dementia-Free Older Adults: A Prospective Cohort Study in Taiwan J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Mu-Cyun Wang, Jeng-Min Chiou, Yen-Ching Chen, Jen-Hau Chen
Abstract Background: Previous studies assessing olfactory function and cognition have mostly been cross-sectional, and few have investigated the Asian geriatric population. Objective: To examine the relationships of olfaction with global or domain-specific cognitive function in Taiwanese community-dwelling older adults. Methods: This cohort study (2015–2019) is part of the Taiwan Initiative for Geriatric
-
S1PR2 Regulates Autophagy Through the AKT/mTOR Pathway to Promote Pathological Damage in Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-12-06 Xiaoping Wang, Rui Huang, Bin Huang, Xiaojia Li
Background: Alzheimer’s disease (AD) is a fatal and debilitating neurodegenerative disease. Sphingosine-1-phosphate receptor 2 (S1PR2), one of the receptors of S1P, is a key regulatory factor for various diseases. Objective: This study aimed to explore the role and possible mechanism of S1PR2 in AD. Methods: S1PR2 expression in the AD mice was detected, and after intervening S1PR2 expression with sh-S1PR2
-
Linking Social Cognition, Parvalbumin Interneurons, and Oxytocin in Alzheimer’s Disease: An Update J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Daniela Černotová, Karolína Hrůzová, David Levčík, Jan Svoboda, Aleš Stuchlík
Abstract Finding a cure for Alzheimer’s disease (AD) has been notoriously challenging for many decades. Therefore, the current focus is mainly on prevention, timely intervention, and slowing the progression in the earliest stages. A better understanding of underlying mechanisms at the beginning of the disease could aid in early diagnosis and intervention, including alleviating symptoms or slowing down
-
Oxidative Stress and Natural Antioxidants: Back and Forth in the Neurological Mechanisms of Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Shalini Mani, Rajni Dubey, I-Chun Lai, M. Arockia Babu, Sakshi Tyagi, Geeta Swargiary, Deepansh Mody, Manisha Singh, Shriya Agarwal, Danish Iqbal, Sanjay Kumar, Munerah Hamed, Punya Sachdeva, Abdulmajeed G. Almutary, Hind Muteb Albadrani, Shreesh Ojha, Sandeep Kumar Singh, Niraj Kumar Jha
Alzheimer’s disease (AD) is characterized by the progressive degeneration of neuronal cells. With the increase in aged population, there is a prevalence of irreversible neurodegenerative changes, causing a significant mental, social, and economic burden globally. The factors contributing to AD aremultidimensional, highly complex, and not completely understood. However, it is widely known that aging
-
Tackling Dementia Together via The Australian Dementia Network (ADNeT): A Summary of Initiatives, Progress and Plans J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Sharon L. Naismith, Johannes C. Michaelian, Cherry Santos, Inga Mehrani, Joanne Robertson, Kasey Wallis, Xiaoping Lin, Stephanie A. Ward, Ralph Martins, Colin L. Masters, Michael Breakspear, Susannah Ahern, Jurgen Fripp, Peter R. Schofield, Perminder S. Sachdev, Christopher C. Rowe
Abstract In 2018, the Australian Dementia Network (ADNeT) was established to bring together Australia’s leading dementia researchers, people with living experience and clinicians to transform research and clinical care in the field. To address dementia diagnosis, treatment, and care, ADNeT has established three core initiatives: the Clinical Quality Registry (CQR), Memory Clinics, and Screening for
-
Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer’s Disease via Neuroinflammation and Ferroptosis J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Jiahui Yang, Xiaohua Shi, Yingying Wang, Ming Ma, Hongyu Liu, Jiaoqi Wang, Zhongxin Xu
Abstract Alzheimer’s disease (AD) is the main cause of dementia in older age. The prevalence of AD is growing worldwide, causing a tremendous burden to societies and families. Due to the complexity of its pathogenesis, the current treatment of AD is not satisfactory, and drugs acting on a single target may not prevent AD progression. This review summarizes the multi-target pharmacological effects of
-
A Literature Review on the Burden of Alzheimer’s Disease on Care Partners J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Kristian Steen Frederiksen, Krista L. Lanctôt, Wendy Weidner, Julie Hviid Hahn-Pedersen, Soeren Mattke
Abstract Background: Many individuals with Alzheimer’s disease (AD) are dependent on nonprofessional care partners. Providing informal care can result in emotional, physical, and financial burdens; however, there is a need for a better understanding of the impact of AD on care partners to support the clinical and economic assessment of potential new treatments. Objective: We conducted a literature
-
Impact of the MIND Diet on Cognition in Individuals with Dementia J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Elizabeth Healy
Background:Alzheimer’s disease (AD) plagues 6.5 million Americans 65+, yet treatments are lacking. The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been developed to address the expansive impact of dementias on the general public. This systematic review evaluated theimpact of the MIND diet on cognition in those with pathologies across the dementia spectrum. Objective:To
-
How Periodontitis or Periodontal Bacteria Can Influence Alzheimer’s Disease Features? A Systematic Review of Pre-Clinical Studies J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Leila Salhi, Yaman Al Taep, Eric Salmon, Dorien Van Hede, France Lambert
Abstract Background: The negative effects of periodontitis on systemic diseases, including diabetes, cardiovascular diseases, and Alzheimer’s disease (AD), have been widely described. Objective: This systematic review aimed to gather the current understanding of the pathophysiological mechanisms linking periodontitis to AD. Methods: An electronic systematic search of the PubMed/MEDLINE, Scopus, and
-
Vacuolar Protein-Sorting Proteins Are Reduced Even Before Cognitive Decline in a Mouse Model of Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Hijiri Shinagawa, Kazuki Ohuchi, Yuya Goto, Kohei Hashimoto, Hideki Kijima, Shogo Maekawa, Hisaka Kurita, Masatoshi Inden
Currently, interventions from the preclinical stage are considered necessary for the treatment of Alzheimer’s disease (AD). Previous studies have reported that vacuolar protein-sorting protein (VPS), a retromer construct, is involved in the pathogenic mechanisms of AD and Parkinson’s disease. Thisstudy evaluated VPS26, VPS29, and VPS35 before and after the onset of cognitive decline in an App knock-in
-
Survival in Incident Cases with Frontotemporal Lobar Degeneration: A Registry-Based Study J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Barbara Borroni, Daniele Urso, Chiara Zecca, Giuliano Binetti, Silvia Fostinelli, Luisa Benussi, Roberta Ghidoni, Barbara Tarantino, Jasmine Rivolta, Maria Teresa Dell’Abate, Antonella Alberici, Giancarlo Logroscino
Population-based registries represent a unique sample to estimate survival. The aim of the present study was to assess survival rates and predictors of outcome in incidental frontotemporal lobar degeneration (FTLD). Incident cases with FTLD, included between January 1, 2017 to December 31, 2017, have been followed for five years. Median survival was 8.16 years from disease onset and 5.38 years from
-
Linking Air Pollution Exposure to Blood-Based Metabolic Features in a Community-Based Aging Cohort with and without Dementia J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-21 Vrinda Kalia, Erin R. Kulick, Badri Vardarajan, Yian Gu, Jennifer J. Manly, Mitchell S.V. Elkind, Joel D. Kaufman, Dean P. Jones, Andrea A. Baccarelli, Richard Mayeux, Marianthi-Anna Kioumourtzoglou, Gary W. Miller
Abstract Background: Long-term exposure to air pollution has been associated with changes in levels of metabolites measured in the peripheral blood. However, most research has been conducted in ethnically homogenous, young or middle-aged populations. Objective: To study the relationship between the plasma metabolome and long-term exposure to three air pollutants: particulate matter (PM) less than 2
-
Precision Medicine Approach to Alzheimer’s Disease: Rationale and Implications J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-07 Dale E. Bredesen, Kat Toups, Ann Hathaway, Deborah Gordon, Henrianna Chung, Cyrus Raji, Alan Boyd, Benjamin D. Hill, Sharon Hausman-Cohen, Mouna Attarha, Won Jong Chwa, Alexei Kurakin, Michael Jarrett
The neurodegenerative disease field has enjoyed extremely limited success in the development of effective therapeutics. One potential reason is the lack of disease models that yield accurate predictions and optimal therapeutic targets. Standard clinical trials have pre-determined a single treatmentmodality, which may be unrelated to the primary drivers of neurodegeneration. Recent proof-of-concept
-
Toward Prevention and Reduction of Alzheimer’s Disease J. Alzheimer’s Dis. (IF 4.0) Pub Date : 2023-11-07 Antonia González-Madrid, Camila Calfío, Andrea González, Valentina Lüttges, Ricardo B. Maccioni
Different investigations lead to the urgent need to generate validated clinical protocols as a tool for medical doctors to orientate patients under risk for a preventive approach to control Alzheimer’s disease. Moreover, there is consensus that the combined effects of risk factors for the disease can be modified according to lifestyle, thus controlling at least 40% of cases. The other fraction of cases